ARROWHEAD PHARMACEUTICALS, INC.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

ARWR$49.00-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 5. OTHER INFORMATION

(c)Trading Plans

During the quarter ended June 30, 2026, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):

Name · Title · Adoption or Termination Date · Plan End Date · Shares Vesting and Subject to Sell-To-Cover (1) · Other Shares Being Sold (Subject to Certain Conditions)
Patrick O’Brien	Chief Operating Officer	04/09/2026	01/08/2027	Up to 30,000 Shares
Patrick O’Brien	Chief Operating Officer	04/09/2026	01/08/2027	81,250
Mauro Ferrari	Board Member	04/14/2026	12/22/2026	3,128

(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.